Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01256450|
Recruitment Status : Completed
First Posted : December 8, 2010
Results First Posted : December 8, 2015
Last Update Posted : February 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pain Low Back Pain||Drug: Buprenorphine Drug: Placebo||Phase 3|
This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-controlled treatment period of 12 weeks. During the double-blind treatment period, this study will evaluate the effectiveness of buprenorphine HCl buccal film versus placebo buccal film in treating CLBP in subjects.
Buprenorphine HCl buccal film is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa. Buprenorphine is a synthetic opioid that is classified as a partial µ-receptor agonist and a Schedule III controlled substance in the United States.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||334 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A 12-Week, Placebo Controlled, Double Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl Buccal Film in Subjects With Moderate to Severe Chronic Low Back Pain|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2011|
Experimental: BEMA Buprenorphine
buprenorphine buccal soluble film
buccal soluble film; applied to the buccal mucosa twice daily
Placebo Comparator: BEMA Placebo
placebo buccal soluble film
buccal soluble film; applied to the buccal mucosa twice daily
- Change in Pain Intensity From Baseline to Week 12 [ Time Frame: Baseline, Week 12 ]Change in pain intensity = average of daily pain scores from the last 7 days prior to week 12 visit - average of daily pain scores for the last 7 days prior to randomization. Average pain intensity over the last 24 hours was rated on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
- Change From Baseline in Pain Intensity Over Time Using NRS Scale [ Time Frame: Baseline; Day 14, Day 28, Day 42, Day 56, Day 70, and Day 84 ]Change in pain intensity = average of daily pain scores from the last 7 days prior to each visit - average of daily pain scores for the last 7 days prior to randomization. Average pain intensity over the last 24 hours was rated on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
- Number of Participants With Response to Treatment as Assessed by an NRS Scale [ Time Frame: Week 12 ]Responses are defined as the relative improvement in pain score at week 12 from baseline, calculated from ratings of average pain intensity over the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
- Percentage of Participants With Treatment Failure in the Double-blind Treatment Phase (up to 12 Weeks) [ Time Frame: Baseline to treatment failure or end of double-blind treatment phase (up to 12 weeks) ]Treatment failure is defined as study discontinuation due to lack of efficacy or due to adverse event in the double-blind treatment phase.
- Subject Impression of Change in Pain Intensity From Baseline to Week 12 Using PGIC Scale [ Time Frame: Baseline, Week 12 ]Subjects assessed changes in activity, limitations, symptoms, and overall quality of life related to their painful condition since beginning treatment using the Patient Global Impression of Change (PGIC), a balanced 7-point scale from 1 (no change or condition got worse) to 7 (a great deal better and considerable improvement that has made all the difference).
- Change From Baseline to Week 12 in Treatment Satisfaction Using TSQM [ Time Frame: Baseline, Week 12 ]The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-item instrument used to assess the subject's satisfaction with the ability of the study medication to prevent or treat the condition of chronic low back pain (CLBP) for effectiveness, side effects, convenience, and global satisfaction. Scores range from 0 to 100, where a higher score indicates less dissatisfaction (ie, greater satisfaction).
- Change From Baseline to Week 12 in Roland Morris Disability Questionnaire [ Time Frame: Baseline, Week 12 ]Subjects assess disability due to back pain using the Roland Morris Disability Questionnaire (RMDQ) consisting of 24 statements of disability. The score of the RMDQ is the total number of items checked, ranging from 0 to 24 with higher scores indicating greater disability.
- Change From Baseline to Week 12 in Subject's Overall Satisfaction With Study Drug [ Time Frame: Baseline, Week 12 ]Subjects were asked to rate their overall satisfaction with their study drug on a 5-point scale ranging from 1 (poor) to 5 (excellent).
- Change From Baseline to Week 12 in Investigator's Overall Satisfaction With Study Drug [ Time Frame: Baseline, Week 12 ]Investigators rated their overall satisfaction with the study drug administered to a given subject on a 5-point scale ranging from 1 (poor) to 5 (excellent).
- Use of Rescue Medication [ Time Frame: Day 7, 14, 28, 42, 56, 70, 84, and 91 within double-blind treatment phase ]Calculated from the use of rescue medication recorded in subject diary as the sum of all rescue medication tablets used in the last 7 days previous to the derived visit, divided by the number of days in this duration where the amount was reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01256450
Show 24 Study Locations
|Study Director:||Andrew Finn, PharmD||BioDelivery Sciences International, Inc.|